Professor & patients' paper on the solvable biological challenge of ME/CFS: reader-friendly version
Simon McGrath provides a patient-friendly version of a peer-reviewed paper which highlights some of the most promising biomedical research on ME/CFS ...
Discuss the article on the Forums.

Acyl-carnitine for the treatment and prevention of viral infections

Discussion in 'Antivirals, Antibiotics and Immune Modulators' started by halcyon, Dec 8, 2014.

  1. halcyon

    halcyon Senior Member

    Messages:
    2,307
    Likes:
    5,391
    I came across this interesting patent application that suggests acetyl-l-carnitine (ALCAR) has potent anti-viral properties, at least in vitro:

     
    sb4 and PeterPositive like this.
  2. Hip

    Hip Senior Member

    Messages:
    9,515
    Likes:
    15,079
    That's very interesting; but unfortunately, if my calculation is correct, it would require an incredibly high dose of 420 grams of acetyl-L-carnitine (ALC) if you wanted it to work as a systemic antiviral for human use.

    (The calculation is this: total fluid volume for a human is around 42 liters or 42,000 ml, so in order to get a ALC concentration of 10 mg per ml in the body, you would need to take a dose of 42,000 x 10 mg = 420,000 mg = 420 grams.)

    This is approaching the LD50 values quoted in the patent, so that dose level would start to become toxic.


    It strange that they found the antiviral effect of ALC either manifested completely, or not at all. This presumably means that smaller doses of ALC would be of no antiviral benefit at all; you would have to take the full dose to get the antiviral effects.

    It is remarkable, though, that ALC completely inhibited the virus, with zero viruses found after the ALC treatment of cells.
     
    Last edited: Dec 10, 2014

See more popular forum discussions.

Share This Page